Veronica Aedo-Lopez
Overview
Explore the profile of Veronica Aedo-Lopez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bandiera C, Cardoso E, Locatelli I, Zaman K, Diciolla A, Digklia A, et al.
PLoS One
. 2024 Jun;
19(6):e0304573.
PMID: 38848380
Background: Oral anticancer therapies such as protein kinase inhibitors (PKIs) are increasingly prescribed in cancer care. We aimed to evaluate the impact of a pharmacist-led interprofessional medication adherence program (IMAP)...
2.
da Silva Lopes A, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, et al.
JMIR Res Protoc
. 2023 Oct;
12:e48386.
PMID: 37851498
Background: Management of severe symptomatic immune-related adverse events (IrAEs) related to immune checkpoint inhibitors (ICIs) can be facilitated by timely detection. As patients face a heterogeneous set of symptoms outside...
3.
da Silva Lopes A, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, et al.
Support Care Cancer
. 2023 Jul;
31(8):484.
PMID: 37480546
Purpose: The use of electronic patient-reported outcome (ePRO) data in routine care has been tied to direct patient benefits such as improved quality of care and symptom control and even...
4.
Hieken T, Kreidieh F, Aedo-Lopez V, Block M, McArthur G, Amaria R
Am Soc Clin Oncol Educ Book
. 2023 Apr;
43:e390614.
PMID: 37116111
Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with or without in-transit metastases, represents approximately 15% of new melanoma diagnoses every year with additional cases presenting as...
5.
Krebs F, Moura B, Missiaglia E, Aedo-Lopez V, Michielin O, Tsantoulis P, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36901951
The development of targeted therapies for non- p.Val600-mutant melanomas remains a challenge. Triple wildtype (TWT) melanomas that lack mutations in , , or form 10% of human melanomas and are...
6.
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612312
The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib is administered orally and cyclically, causing medication adherence challenges. We evaluated components of adherence to palbociclib, its relationship with pharmacokinetics (PK), and drug-induced...
7.
Gautron Moura B, Gerard C, Testart N, Caikovski M, Wicky A, Aedo-Lopez V, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612030
Combined ipilimumab and nivolumab significantly improve outcomes in metastatic melanoma patients but bear an important financial impact on the healthcare system. Here, we analyze the treatment costs, focusing on irAE....
8.
Luong V, Ho C, Aedo-Lopez V, Segelov E
Front Surg
. 2022 Aug;
9:962120.
PMID: 35923437
Introduction: Gender equity in medicine has become a significant topic of discussion due to consistently low female representation in academia and leadership roles. Gender imbalance directly affects patient care. This...
9.
Mounnarath E, Zwieky W, Aedo-Lopez V, Fazli O, Sheridan B
SAGE Open Med Case Rep
. 2022 May;
10:2050313X221097265.
PMID: 35573098
The Wilms tumour is the fourth most common paediatric malignancy. On the contrary, it is extremely rare in adults as it accounts for less than 1% of all renal malignancies....
10.
Aedo-Lopez V, Gerard C, Boughdad S, Gautron Moura B, Berthod G, Digklia A, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267470
To assess the safety and efficacy of ipilimumab plus nivolumab around selective internal radiation therapy (SIRT) in patients with metastatic uveal melanoma (mUM). We present a retrospective, single center study...